- Home
- HRMY vs MBIN Comparison
HRMY vs MBIN Comparison
Compare HRMY & MBIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- MBIN
- Stock Information
- Founded
- HRMY 2017
- MBIN 1990
- Country
- HRMY United States
- MBIN United States
- Employees
- HRMY N/A
- MBIN N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- MBIN Major Banks
- Sector
- HRMY Health Care
- MBIN Finance
- Exchange
- HRMY Nasdaq
- MBIN Nasdaq
- Market Cap
- HRMY 1.8B
- MBIN 1.6B
- IPO Year
- HRMY 2020
- MBIN 2017
- Fundamental
- Price
- HRMY $34.94
- MBIN $30.81
- Analyst Decision
- HRMY Strong Buy
- MBIN Buy
- Analyst Count
- HRMY 9
- MBIN 3
- Target Price
- HRMY $55.33
- MBIN $38.33
- AVG Volume (30 Days)
- HRMY 627.0K
- MBIN 207.4K
- Earning Date
- HRMY 08-05-2025
- MBIN 07-28-2025
- Dividend Yield
- HRMY N/A
- MBIN 1.31%
- EPS Growth
- HRMY 58.41
- MBIN N/A
- EPS
- HRMY 3.10
- MBIN 4.55
- Revenue
- HRMY $772,527,000.00
- MBIN $598,079,000.00
- Revenue This Year
- HRMY $20.45
- MBIN $1.16
- Revenue Next Year
- HRMY $17.32
- MBIN $9.35
- P/E Ratio
- HRMY $11.29
- MBIN $6.71
- Revenue Growth
- HRMY 17.74
- MBIN N/A
- 52 Week Low
- HRMY $26.47
- MBIN $27.25
- 52 Week High
- HRMY $41.61
- MBIN $47.94
- Technical
- Relative Strength Index (RSI)
- HRMY 50.27
- MBIN 39.84
- Support Level
- HRMY $34.09
- MBIN $28.75
- Resistance Level
- HRMY $36.09
- MBIN $35.16
- Average True Range (ATR)
- HRMY 1.42
- MBIN 1.20
- MACD
- HRMY -0.19
- MBIN -0.59
- Stochastic Oscillator
- HRMY 46.42
- MBIN 28.81
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About MBIN Merchants Bancorp
Merchants Bancorp is a United States based bank holding company. It operates multiple lines of business focusing on FHA (Federal Housing Administration) multi-family housing and healthcare facility financing and servicing, retail and correspondent residential mortgage banking, and traditional community banking. The business segments of the company are: Multi-family Mortgage Banking which originates and services government-sponsored mortgages for multi-family and healthcare facilities; Mortgage Warehousing segment which funds agency-eligible residential loans as well as commercial loans to nondepository financial institutions; and the Banking segment, which generates maximum revenue, and provides various financial products and services to consumers and businesses.